SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as the market reacts to the company's latest subscription price hikes, which analysts view as a strategic move to fund a massive content budget and solidify profitability. While some retail investors are voicing frustration over recurring cost increases, the community is heavily focused on the stock's relative strength and technical breakout potential, with many discussing its role as a hedge against broader market volatility.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is currently trending following news that it has secured FDA approval for VYKAT XR, the first therapy developed to treat hyperphagia in Prader-Willi syndrome. The community is actively discussing the stock's significant price momentum, debating the potential for a future acquisition by a larger pharmaceutical player, and evaluating the long-term commercial execution of this newly approved asset.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is experiencing a significant surge in momentum as the company reports positive trial results for its essential tremor and epilepsy therapies, driving multiple analyst price target upgrades. While the community is debating the impact of a recent large-scale public offering, many investors remain bullish on the long-term potential of the company's CNS-focused pipeline.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending due to a definitive agreement to acquire Soleno Therapeutics for $53 per share in an all-cash deal valued at approximately $2.9 billion. Community sentiment is mixed, with some investors debating the valuation and strategic rationale of the acquisition, while others are pressuring management to accelerate pipeline development or consider selling the company to unlock shareholder value.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind this Solana-based meme coin as a satirical movement intended to mock established market structures, with community members actively comparing its long-term potential to industry giants. Discussions are currently dominated by enthusiasts promoting the token's cultural narrative and its goal of creating viral engagement within the broader crypto ecosystem.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics is seeing significant market interest as investors focus on its role as a key optics supplier for the U.S. defense sector, particularly for high-tech augmented reality and missile guidance systems. The community is actively discussing the stock's potential for long-term growth driven by defense contracts and its tight supply structure, while debating the volatility caused by high short-selling interest and the company's capital needs.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors gain confidence in the company's shift toward AI-native infrastructure and telecommunications, bolstered by strategic partnerships and recent institutional accumulation. The community is actively discussing its potential for a long-term breakout, often drawing parallels to its role in the next generation of mobile connectivity and high-tech defense contracts.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying as investors react to a strategic $14.2 billion deal to regain full ownership of its Ireland-based Fab 34, a move perceived as a major vote of confidence in the company's manufacturing and AI-driven growth trajectory. The community is actively debating the stock's future, with many interpreting the heavy capital reinvestment as a clear indicator that major new customer contracts are imminent.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology is experiencing significant market attention as analysts raise price targets and designate it a top pick, citing strengthened hard disk drive demand and supply constraints that are expected to persist for several years. The community is actively debating the stock's massive rally, with sentiment split between optimism over sustained hyperscaler demand and caution regarding potential valuation exhaustion compared to industry peers.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is currently a focal point for investors as it approaches a key clinical presentation at the upcoming ASH annual meeting, with community sentiment centering on the potential for a strategic buyout or major partnership given the company's strong profitability and growing cash position. Despite recent volatility and aggressive short-selling activity, stakeholders remain intensely focused on the long-term value of the IRAK1/4 pipeline and the company's transition into a self-sustaining commercial entity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aberdeen Group plc Raises Holdings in Oculis Holding AG $OCS

Aberdeen Group plc boosted its position in Oculis Holding AG (NASDAQ:OCS - Free Report) by 39.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund...

Oculis (NASDAQ:OCS) Trading Up 9.2%  - Time to Buy?

Oculis (NASDAQ:OCS) Shares Up 9.2% - Should You Buy...

Short Interest in Oculis Holding AG (NASDAQ:OCS) Declines By 21.5%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 490,094 shares, a drop of 21.5% from the February 26th total of 623,971 shares. Based on an average trading volume of...

Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have given...

Syquant Capital Sas Invests $3.85 Million in Oculis Holding AG $OCS

Syquant Capital Sas purchased a new position in Oculis Holding AG (NASDAQ:OCS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 192,722 shares of the company's stock, valued at appro...

Short Interest in Oculis Holding AG (NASDAQ:OCS) Expands By 63.9%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 623,971 shares, an...

Oculis (NASDAQ:OCS) Sees Large Volume Increase - Here's What Happened

Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume - Here's What Happened...

Oculis (NASDAQ:OCS) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen lowered Oculis from a "hold" rating to a "sell" rating in a research note on Saturday...

HC Wainwright Weighs in on Oculis' Q1 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2026 earnings estimates for Oculis in a research report issued to clients and investors on...

Lifesci Capital Estimates Oculis' Q1 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS - Free Report) - Lifesci Capital decreased their Q1 2026 earnings per share estimates for shares of Oculis in a report released on Wednesday, March 4th. Lifesci Capital...

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Oculis Holding AG

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.51	--	--	N/A
Q4 '25	-$0.50	-$0.52	-5.57%	MISSED
Q3 '25	-$0.51	-$0.41	19.73%	BEAT
Q2 '25	-$0.52	-$0.61	-17.06%	MISSED
Q1 '25	-$0.52	-$0.85	-63.10%	MISSED

OCS
Oculis Holding AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest OCS News

OCSOculis Holding AG